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Abstract
Donors to biobanks are typically asked to give blanket consent, allowing their donation
to be used in any research authorized by the biobank. This type of consent ignores
the evidence that some donors have moral, religious, or cultural concerns about
the future uses of their donations – concerns we call “non-welfare interests”. The
nature of non-welfare interests and their effect on willingness to donate to a
biobank is not well understood.
In order to better undersand the influence of non-welfare interests, we surveyed a
national sample of the US population (in June 2014) using a probability-based internet
panel. Logistic regression models assessed the demographic and attitudinal
characteristics associated with participants’ willingness to give consent for unspecified
future uses of their donation when presented with 7 research scenarios that raised
possible non-welfare interest concerns.
Most people had non-welfare interests that significantly affect their willingness
to donate to a biobank using blanket consent. Some non-welfare interests are
associated with subgroups but others are not. A positive attitude toward
biomedical research in general was associated with increased willingness to donate,
while concerns about privacy and being African American were associated with
decreased willingness.
Non-welfare interests matter and can diminish willingness to donate to a biobank. Our
data suggest that trust in research promotes willingness to donate. Ignoring non-
welfare interests could erode this trust. Donors’ non-welfare interests could be
accommodated through greater transparency and easier access to information
about the uses of donations.
Keywords: Biobank, Biobank donors, Bioethics, Blanket consent, Moral concerns,
Non-welfare interests, Research attitudes questionnaire, Willingness to donate
Introduction
Biobanking is becoming an increasingly important platform for medical, and specific-
ally genetic, research conducted in the United States and around the world. Having
access to curated, centralized repositories of biospecimens, along with their associ-
ated demographic and clinical data, allows researchers to perform more efficient and
less costly studies, shortening the pipeline from concept to clinical care. Biobanked
samples have already been used to understand the genetics of multiple sclerosis (The
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International Multiple Sclerosis Genetics Consortium 2011), to improve treatments
for conditions such as prostate cancer (Akamatsu et al. 2012), to identify a causal link
between HPV and cervical cancer (Lehtinen et al. 1996; Wallin et al. 1999), and to
study the genomics of cancer formation (George et al. 2015). As the value of
genetically-based personalized medicine expands, so too will the role of biobanking
(Hewitt 2011).
The promise of biobank research must, however, be balanced against the risk of con-
troversy created when people become passive participants in research about which they
have no direct knowledge. A well-known example is the research conducted by Arizona
State University researchers using blood collected from members of the Havasupai
tribe. Although the blood was originally collected for research on diabetes, the consent
was designed to cover any “behavioral/medical” research. When the tribe later discov-
ered that their samples were also used to look for genetic drivers of schizophrenia, they
were offended and angry (Van Assche et al. 2013). A more recent case occurred in
Texas where the Department of State Health Services – like many state departments of
health – routinely collects newborn bloodspots. Parents of newborns there were upset
when they learned that researchers were using the bloodspots without their consent or
knowledge. Their concern was exacerbated by the fact that researchers could connect
genetic information from the blood spots to other personal information in the state’s
possession. The parents successfully sued the researchers and more than 5 million sam-
ples were destroyed (Lewis et al. 2012).
These cases make visible public concerns about research and exemplify the ways
our current ethical and legal frameworks lag behind advances in science and technol-
ogy. Certain types of research that use biobanked samples, cloning and genetic modi-
fication among them (Baker 2014; Liang et al. 2015), create worries about “playing
God,” violating privacy, and discrimination by employers and insurers (Bates et al.
2005; Kaufman et al. 2009; Lemke et al. 2010; McDonald et al. 2014; Shabani et al.
2014; Trinidad et al. 2010). The lack of adequate protections for donors intensifies
these worries, generating public dissatisfaction with, and distrust of, the research
community. Diminished trust in the work of science poses a significant threat to its
future in terms of funding and willingness to participate in research.
At the center of this challenge is the question of how best to inform biobank donors
about the kinds of research that might use their tissue—a challenge that begins with
the initial consent. Biobanks store biospecimens from a variety of sources for future, as
yet unknown, research. Neither the biobank donors nor the biobank know with any
certainty what kinds of research might eventually use their donated samples—a chal-
lenge to the traditional notion of “informed” consent. In light of this, many large popu-
lation biobanks have adopted a model where the donor consents to future unknown
uses of the specimen, without any additional specific consent, and with no provision of
information about how the donation has been used (see for example, www.mayo.edu/
research/documents/biobank-consent-formpdf/DOC-10027511).
At present, various terms are used to describe this type of consent. The term “blanket
consent” is sometimes used to mean completely unregulated consent with no oversight
mechanisms at all (Knoppers et al. 2013), with “broad consent” referring to consent for un-
specified uses with some degree of oversight (Grady et al. 2015). Others use “broad consent”
as a generic reference to any type of consent that covers a range of future uses (including
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blanket consent) (Gefenas et al. 2012; Petrini 2010). We chose to test a model portraying
“blanket consent” with “committee oversight” (see description below in Methods) as a way
of focusing on the ethical issue of consenting to future unknown uses of biospecimens –
the central issue in the conversation about informed consent for biobanking.
Biobanks take care to de-identify the samples in order to protect the interests and
welfare of donors. As such, any analysis conducted using the specimen will not directly
affect the donor. Under this model, the donor is generally not even aware that research
using their specimen is being conducted. For these reasons, many have argued that a
blanket consent model is sufficient to protect participants and uphold standards of in-
formed consent (Rothstein 2005; Office for Human Research Protections 2008)—a pos-
ition that aligns with proposed changes to the Common Rule (Office for Human
Research Protections 2015).
However, this ethical framework is problematic because it does not address the
moral, religious, or cultural concerns that donors may have about how their donations
are used—concerns we refer to as “non-welfare interests” (NWIs) (Tomlinson 2013;
Tomlinson et al. 2014). Current research regulations are primarily concerned with pro-
tecting people from various kinds of harms; that is, protecting their welfare interests.
Our use of the term “non-welfare interest” highlights concerns that are deeply import-
ant to research participants but that are ignored in current regulations. The Havasupai,
for example, had a non-welfare interest in how their donations were used. If they had
not learned about the schizophrenia research, arguably no harm would have come to
them. But because they found out, we now know that they cared deeply about how
their samples were used. If they had been told about other possible research using their
donated blood, they may have withheld their consent. Existing research has shown that,
although the public is largely comfortable with authorizing the use of their samples for
unspecified future research (Wendler 2006), they also have significant moral concerns
about how their specimens might be used—even if they are unaware of such uses
(Gornick et al. 2014; Wendler 2006).
Using a nationally representative sample of the public, we recently showed that NWIs
do indeed influence willingness to donate to a biobank. When presented with potential
research scenarios that raised moral concerns – e.g., related to abortion, genetic re-
search, and biological weapons – our respondents’ willingness to donate to a biobank
using a blanket consent was associated with NWIs, and sometimes diminished signifi-
cantly (Tomlinson et al. 2015).
Given the convincing evidence that NWIs do exist and do influence willingness to do-
nate to biobanks, it is critically important that we understand the drivers of these con-
cerns. If we are to ensure that all segments of the population are represented in biobanks
we must be able to respond to the concerns that disincline certain people to donate
(McDonald et al. 2014). In this paper, we closely examine the demographic and attitudinal
characteristics associated with the influence of NWIs on willingness to donate.
Materials and Methods
Study population
A nationally representative sample of the US population was surveyed in June 2014 to
explore the effects of non-welfare interests on the willingness to donate to a biobank.
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Participants were recruited from a probability-based internet panel (KnowledgePanel®)
managed by GfK Knowledge Networks, a survey research firm. KnowledgePanel con-
sists of about 55,000 adults (ages 18 and older), representing a probability sampling of
97 % of U.S. households. It recruits households by randomly selecting residential
addresses using “address-based sampling” (ABS) which provides statistically valid repre-
sentation of the U.S. population. The firm’s recruitment and statistical weighting
methods are described elsewhere in greater detail (GfK Knowledge Networks 2013).
Of the 2,654 eligible panel members contacted, 1,638 completed the survey. After ex-
cluding data from 39 respondents who either answered fewer than half of the survey
questions or who completed the survey in less than 2 min, the current study examines
data from 1,599 respondents (60.2 % response rate). Compared to non-respondents, re-
spondents were somewhat older, were more likely to be white, and had higher levels of
education and household income. A description of the socio-demographic characteris-
tics of respondents and non-respondents can be found elsewhere (Tomlinson et al.
2015). All results, including descriptive statistics, were weighted to correct for stratified
sampling designs, non-coverage, and non-response.
The study was reviewed by the Institutional Review Boards at the University of
Michigan and Michigan State University and deemed exempt from federal regulations.
Survey measures
Our survey was developed to explore the effects that non-welfare interests might have
on the willingness to donate to a biobank, as well as preferences for biobank consent
policies (not discussed here). The survey contained a brief introductory description of
the function, purpose, and potential societal benefits of a fictional biobank, as well as a
description of ‘blanket consent’ as follows:
“…you will let the biobank use your sample in any study done by researchers who
use the biobank. The biobank cannot predict what kind of projects will be done in
the future. Thus, it cannot know which future projects will use your sample when
you donate. It may happen that your sample is never used… Before a researcher can
use your biobank sample, a committee must review the study. This committee will
make sure the study is well designed, protects your privacy, and will help society.”
Following the introduction, we used a short 6-item true/false questionnaire to test
subjects’ comprehension of the introductory biobank description. The average number
of correct responses was 5.1.
As a baseline for blanket consent, respondents were asked to rate how strongly they
agreed or disagreed (on a 6-point scale, 1 = Strongly Disagree, 6 = Strongly Agree) with
this willingness to donate statement: “I would donate tissue samples and medical infor-
mation to the biobank, so that it can use them for any research study that it allows,
without further consent from me.”
After that baseline question, respondents were introduced to a description of non-
welfare interests as follows:
“Research using biobanked samples will help others in the future because it may
lead to better ways of finding and preventing disease. For example, it may help
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researchers find treatments for diseases like cancer. However, some types of research
that could be done with biobanked samples might worry some donors because the
research might conflict with their religious, cultural, or philosophical beliefs.”
They were then asked to rate their willingness to provide blanket consent “even if”
researchers might use their samples in each of 7 (randomly ordered) research scenar-
ios presenting moral concerns. The scenarios were based on potential NWI concerns
identified by others (People Science & Policy Ltd 2003; Haddow et al. 2007; National
Research Council and Institute of Medicine 2005; Pfeffer 2008; Selgelid 2009; Tomlinson
2009) and described research to:
1) Develop more safe and effective abortion methods (Abortion);
2) Develop kidney stem cells. The goal would be to grow human kidneys or other
organs in a pig that could then be transplanted into people (Xenotransplant);
3) Develop patents and earn profits for commercial companies. Most new drugs
used to treat or prevent disease come from commercial companies (Patents);
4) Develop stem cells that have the donor’s genetic code. Scientists might use those
stem cells to create many different kinds of tissues and organs for use in medical
research (Stem cells);
5) Create vaccines against new biological weapons. The government might need to
develop biological weapons of its own when it does this research (Bioweapons);
6) Understand the evolution of different ethnic groups, and where they come from.
What they learn might conflict with some religious or cultural beliefs (Evolution);
7) Discover genes that make some people more violent. This could lead to ways to
reduce violent behavior. But if these genes are found to be more common among
some racial and ethnic groups, this might increase prejudice (Violence gene).
We also collected a number of demographic and attitudinal variables (see Table 1) in-
cluding a measure of “residual privacy concern,” i.e., how worried respondents would
be that an unauthorized person might see their private information, even after being
told a “committee will make sure the study…protects your privacy” (on a 5-point scale,
1 = “Not worried at all”, 5 = “Very Worried”), and their opinion of biomedical research
in general (using the RAQ – Research Attitudes Questionnaire) (Rubright et al. 2011).
Statistical analysis
The primary outcome variable of interest was willingness to donate. For blanket con-
sent and each of the seven scenarios with NWI concerns, we dichotomized the level
of agreement with the “willingness to donate” statement – ranging from 1 to 6 – to
“willing” (scores of 4, 5 or 6) and “unwilling” (1, 2 or 3). To understand the effect of
potential donors’ socio-demographic characteristics and their attitudes on willingness
to donate in the different NWI scenarios, a separate logistic regression model of will-
ingness was fit for each of the seven “non-welfare interests” research scenarios. We
considered all participant characteristics (summarized in Table 1) as potential predictors
of interest. In order to determine the nature of the relationships – linear or non-
linear – between predictors and our outcome variable, we first fit all potential predic-
tors that were continuous or ordinal as categorical dummies. If we found a strong
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Table 1 Socio-demographics of participants by dichotomized willingness to donate using blanket
consent (baseline)a and total sample
Agree 1083 (68 %) Disagree 510 (32 %) Total 1593 p-valueb
Age (years), mean (SD) 48.8 (16.5) 46.5 (15.1) 48.1 (16.1) .02
Female 569 (68.6 %) 261 (31.4 %) 830 (52.1 %) .64
Race < .001
White 888 (70.9 %) 364 (29.1 %) 1252 (78.6 %)
Black/African American 92 (48.9 %) 96 (51.1 %) 188 (11.8 %)
Otherc 103 (67.5 %) 50 (32.5 %) 153 (9.6 %)
Hispanic 135 (58.8 %) 95 (41.2 %) 230 (14.5 %) .001
Education < .001
< High School 104 (56.2 %) 81 (43.8 %) 185 (11.6 %)
High school 304 (64.5 %) 167 (35.5 %) 472 (29.7 %)
Some college 305 (68.0 %) 144 (32.0 %) 448 (28.3 %)
≥ Bachelor’s Degree 370 (75.8 %) 118 (24.2 %) 487 (30.5 %)
Household incomed < .001
< $50,000 408 (62.1 %) 249 (37.9 %) 656 (41.2 %)
$50,000–$99,999 349 (69.4 %) 154 (30.6 %) 503 (31.6 %)
> $100,000 326 (75.3 %) 107 (24.7 %) 433 (27.2 %)
Attend religious service .03
≥ Once a month 420 (65.7 %) 219 (34.3 %) 639 (40.4 %)
< Once a month 374 (73.1 %) 138 (26.9 %) 511 (32.3 %)
Never 286 (66.2 %) 146 (33.8 %) 432 (27.3 %)
Religion < .001
Catholic 246 (71.8 %) 97 (28.2 %) 343 (21.7 %)
Non-Catholic Christian 485 (67.8 %) 230 (32.2 %) 715 (44.9 %)
Non-Christian Religions 61 (75.5 %) 20 (24.6 %) 81 (5.1 %)
Unaffiliated 255 (71.4 %) 102 (28.6 %) 357 (22.6 %)
Do not know/Refused 33 (36.2 %) 57 (63.8 %) 90 (5.7 %)
Evangelical 260 (66.0 %) 134 (34.0 %) 395 (41.7 %) .04
Political view .004
Liberal 327 (74.9 %) 109 (25.1 %) 437 (27.6 %)
Moderate 394 (65.8 %) 205 (34.2 %) 599 (37.9 %)
Conservative 354 (64.8 %) 193 (35.2 %) 546 (34.5 %)
Region .02
Northeast 185 (64.2 %) 103 (35.8 %) 288 (18.1 %)
South 391 (66.1 %) 201 (33.9 %) 592 (37.2 %)
West 250 (67.3 %) 121 (32.7 %) 372 (23.4 %)
Midwest 256 (75.3 %) 84 (24.7 %) 340 (21.4 %)
Employment status .001
Working 643 (70.6 %) 268 (29.4 %) 911 (57.2 %)
Looking for work/laid off 83 (53.9 %) 71 (46.1 %) 154 (9.7 %)
Retired 196 (71.8 %) 77 (28.2 %) 273 (17.2 %)
Not working, disabled 66 (58.1 %) 48 (41.9 %) 114 (7.2 %)
Not working, other 95 (67.3 %) 46 (32.7 %) 141 (8.9 %)
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linear relationship – i.e., if the parameter estimates for the categorical dummy vari-
ables increased incrementally – we included that variable as a continuous variable.
For example, privacy was included in the model as a single continuous variable ran-
ging from not worried at all (1) to very worried (5). Similarly, political affiliation was
included as a single variable going from extremely liberal (1) to extremely conserva-
tive (7).
Predictors that showed no meaningful relationship with willingness to donate under
any of the scenarios – determined by parameter estimates close to null with corre-
sponding p-values greater than 0.05 – were dropped from the model. (See Table 1) For
consistency in presentation and interpretation, the final model for each scenario in-
cluded the same set of predictors that showed a meaningful relationship with willing-
ness to donate under at least one scenario. Adjusted odds ratios (AOR) and the 95 %
confidence intervals associated with each predictor were obtained based on the model
parameter estimates. An AOR greater than 1 indicates a participant characteristic posi-
tively associated with willingness to give consent, an AOR less than 1 indicates a char-
acteristic negatively associated with willingness to give consent, while holding other
characteristics in the model constant. As noted above, all results including descriptive
statistics were weighted to correct for stratified sampling designs, non-coverage and
non-response.
Results
We found an overall shift in willingness to donate using blanket consent when respon-
dents were asked to consider scenarios that raised the possibility of NWIs (Tomlinson
et al. 2015). Of the 1,593 participants who responded, a majority – 68 % – agreed with
the baseline consent statement: “I would donate tissue samples and medical informa-
tion to the biobank, so that the biobank can use them for any research study that it
Table 1 Socio-demographics of participants by dichotomized willingness to donate using blanket
consent (baseline)a and total sample (Continued)
Ownership of housing .008
Owned 779 (70.2 %) 331 (29.8 %) 1109 (69.7 %)
Rented 276 (64.7 %) 151 (35.4 %) 428 (26.9 %)
Occupied w/o cash rent 28 (49.7 %) 28 (50.3 %) 56 (3.5 %)
Household has internet 881 (70.6 %) 368 (29.4 %) 1248 (78.4 %) < .001
Privacye, mean (SD) 2.6 (1.2) 3.6 (1.2) 2.9 (1.3) < .001
RAQf, mean (SD) 46.0 (6.9) 38.1 (7.8) 43.5 (8.1) < .001
Abortion viewg, mean (SD) 2.6 (1.0) 2.4 (1.0) 2.4 (1.0) .001
N = 1,593; Cell values are weighted counts (%) or weighted means (SD); Other variables collected, but are not included in
the table are not associated with participant position on blanket consent: marital status (p = 0.21), head of household
(p = 0.47), household size (p = 0.37), metropolitan area (p = 0.93), housing type (p = 0.48), whether household members
include at least one child (p = 0.12)
a“I would donate tissue samples and medical information to the biobank, so that the biobank can use them for any
research study that it allows, without further consent from me. Please indicate your level of agreement with
the statement:”
bFrom survey weight adjusted Х-square test for comparisons between those who agreed vs. not to blanket consent for
all participant characteristics and survey weight adjusted t-test for age and RAQ
cAmerican Indian, Alaskan Native, Asian, Native Hawaiian/Pacific Islander, 2+ races
dCollapsed from 19 levels
eRange is 1 to 5 (higher is more worried)
fRAQ is the 11 item Research Attitudes Questionnaire, assessing attitudes toward medical research. Range is 11–66
(higher score means more positive attitudes)
gRange is 1 (always legal) to 4 (always illegal)
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allows, without further consent from me.” In all but one of the NWI scenarios – the
exception being “stem cells” – the willingness to donate using blanket consent dimin-
ished significantly. The percent willing to donate in each (with the p-value of the dif-
ference from the baseline of 68 %, using conditional logistic regression to examine
the paired binary willingness responses for each participant) were: Abortion (49.5 %,
p < .001), Xenotransplant (64.2 %, p = .007), Patents (55.2 %, P < .001), Stem cells
(70.1 %, p = .17), Bioweapons (56.5 %, p < .001), Evolution (64.0 %, p = .005), Vio-
lence gene (58.1 %, p < .001). Among the 1,083 respondents who were willing to do-
nate using blanket consent at baseline, 762 (70.4 %) were unwilling to donate using
blanket consent in at least one NWI scenario (Tomlinson et al. 2015).
Baseline willingness: willingness to donate using blanket consent
Table 1 reports participant characteristics for all respondents and for those willing and
unwilling to donate using blanket consent, before they were asked to consider research
projects that may raise NWI concerns. Unadjusted comparison between those willing
vs. not willing to donate at baseline shows race, ethnicity, education, household income,
religion, political views (ranging from extremely liberal to extremely conservative),
views on abortion, employment status, ownership of housing, and internet access to be
strongly associated with willingness. Attitudes toward biomedical research and residual
concern about privacy are also significantly associated with willingness.
In adjusted analyses using logistic models, residual concern about privacy and atti-
tudes toward research were the most powerful predictors: greater concern about priv-
acy was associated with lower willingness to donate (p < 0.001, Table 2), while a
positive attitude toward research was associated with greater willingness (p < 0.001,
Table 2). When we controlled for privacy and attitudes toward research, only one of
the other variables in our model – race – had an association with willingness to do-
nate: African Americans remained significantly less willing to donate after adjusting
for all the other variables, including views on privacy and attitudes towards research
(p < 0.001).
Willingness to donate using blanket consent, when considering scenarios with potential
NWI concerns
Table 3 presents the predictors of willingness to donate using blanket consent, after
learning the specifics of each of the NWI scenarios. Looking first at the effect of
respondent characteristics on willingness to donate, we found that across all seven
scenarios more positive attitudes toward research were associated with significantly
greater willingness to donate. Conversely, one’s education and household income
were not associated with willingness to donate in any of the NWI scenarios. Simi-
larly, one’s religious affiliation had no strong or consistent effect on willingness to
donate in the various scenarios.
Older age reduced willingness to donate in four of the seven NWI scenarios: abor-
tion, bio-weapons, evolution, and violence gene. Residual concern with privacy –
strongly associated with lower willingness to donate at baseline (i.e. before exposure
to NWIs) – decreased willingness to donate in three of the seven scenarios – xeno-
transplant, stem cells, and evolution – and was marginally significant (p = .06) in the
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bioweapons scenario. African American identity – another variable strongly associ-
ated with unwillingness to donate at baseline – was a significant independent pre-
dictor of decreased willingness to donate in two NWI scenarios: xenotransplantation
and the search for a violence gene.
It is also instructive to look at how, and where, each scenario influenced willingness
to donate. Two NWI scenarios, patents and bioweapons, diminished willingness to
donate by more than 10%age points in the overall sample, but proved to be more or
less “non-partisan” in their effect on willingness to donate. That is, respondent char-
acteristics that we would expect to exert influence here – one’s political views and
view on abortion – were not associated with decreased willingness to donate, and reli-
gion had a minimal effect. On the other hand, the stem cell scenario, which did not
Table 2 Logistic regression predicting willingness to donate using blanket consent (at baseline)a,b
AORc SE 95 % CI p-value
Age (in years) 1.00 0.00 (0.99, 1.01) 0.57
Female 1.16 0.16 (0.88, 1.52) 0.30
Race
White 1.00 – – –
Black/African American 0.46 0.11 (0.29, 0.73) < 0.001
Other 1.01 0.28 (0.58, 1.73) 0.98
Hispanic 0.78 0.18 (0.50, 1.22) 0.27
Educationd 0.93 0.08 (0.79, 1.09) 0.38
Household Income (1–19) 1.01 0.02 (0.98, 1.05) 0.40
Abortion view
Always legal 1.00 – – –
Legal in most circumstances 1.15 0.25 (0.76, 1.76) 0.51
Legal in a few circumstances 1.09 0.23 (0.72, 1.63) 0.69
Always illegal 0.90 0.23 (0.55, 1.47) 0.66
Don’t know 0.96 0.30 (0.52, 1.77) 0.89
Religious affiliation
Catholic 1.00 – – –
Non-Catholic Christian 0.98 0.18 (0.69, 1.41) 0.93
Non-Christian Religions 0.92 0.33 (0.46, 1.84) 0.81
Unaffiliated 1.06 0.24 (0.68, 1.64) 0.80
Do not Know/Refused 0.59 0.23 (0.27, 1.28) 0.18
Politicale 0.92 0.05 (0.83, 1.02) 0.10
Privacyf 0.68 0.04 (0.60, 0.77) < 0.001
RAQg 1.13 0.01 (1.10, 1.16) < 0.001
N = 1,593
aWe define blanket consent as a model in which the donor gives permission for unspecified and unknown uses of the
specimen at the time of donation. We chose to test a model portraying “blanket consent” with “committee oversight”
as a way of focusing on the ethical issue of consenting to future unknown uses of biospecimens – the central issue in
the conversation about informed consent for biobanking
bAdjusted for post-stratification weights
cAOR (Adjusted Odds Ratio) greater than 1 means the participant characteristic is positively associated with willingness
to give blanket consent, and less than 1 means the characteristic is negatively associated with willingness to give
blanket consent
dRange is 1 to 4 (higher is more education)
eRange is 1 to 7 (higher is more conservative)
fRange is 1 to 5 (higher is more worried)
gRAQ is the 11 item Research Attitudes Questionnaire, assessing attitudes toward medical research. Range is 11–66
(a higher score corresponds to more positive attitudes)
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Table 3 Logistic regression predicting willingness to give consent under non-welfare interest scenariosa (Continued)
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(Adjusted Odds Ratio) greater than 1 means the participant characteristic is positively associated with willingness to give blanket consent, and less than 1 means the characteristic is negatively associated with
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(higher is more conservative)
dRange is 1 to 5
(higher is more worried)
eRAQ is the 11 item Research Attitudes Questionnaire, assessing attitudes toward medical research. Range is 11–66
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* p < .05














reduce willingness to donate in the survey, significantly reduced willingness to donate
among political conservatives and those with residual concerns about privacy
(Table 3).
Discussion
Our national survey shows that concern with one’s non-welfare interests (NWIs) has a
significant effect on willingness to donate to a biobank using blanket consent (Tomlinson
et al. 2015). More than 70% of the respondents who were willing to donate using a blanket
consent – before being told of the possibility of research that could raise moral, religious,
or cultural concerns – became unwilling to donate with a blanket consent in at least one
of seven proposed research scenarios associated with NWIs. Thus, when they are made
apparent, NWI concerns matter to most people. But not unexpectedly, there is variation
in which NWI scenarios matter to which people. Some NWI scenarios – like those involv-
ing patents and bioweapons – are of general concern to potential donors, unrelated to a
person’s demographic and attitudinal characteristics, while others are of particular con-
cern to certain subgroups.
These data suggest that the current policy of asking potential donors to consent to all
future uses of their donations may be empirically and ethically shortsighted. Empiric-
ally, we know that NWIs matter. Given our findings and the many future unknown
uses of biobanked materials, it is clear that this is an issue that will affect virtually all
donors. Ethically, we know that informed consent is problematic if information material
to the decision to be made is withheld. Since we know that NWIs are material for most
donors, a policy that deliberately avoids any mention of potential donor concerns could
undermine the adequacy of the consents given by some donors.
The challenge for biobanks is to design a set of policies that can account for the var-
ied levels of concern about NWIs found in the population. Some may argue that con-
cerns that matter to only a minority of donors are too costly to be addressed at all by a
biobank. There are two problems with this conclusion, one specific and one general. In
the first instance, policies based solely on the concerns of the majority – determined by
surveys or representation by groups in power – will discourage donations from minor-
ity groups who may have good reasons to be wary of research, depriving biobanks of
donations representing that subgroup. Second, ignoring concerns held by a minority of
citizens overlooks the potential positive impact of a transparent public information pol-
icy that promotes trust in the work of science.
Our study confirms that trust is critical in the decision to donate (Critchley et al.
2015; Ridgeway et al. 2013). A positive attitude toward biomedical research in gen-
eral – as measured by the RAQ – was consistently associated with increased willing-
ness to donate, both before and after being exposed to scenarios with NWI concerns.
Although not as consistent an effect, residual concern with privacy – i.e., trust that
researchers will protect personal information – was associated with decreased willingness
to donate. We also found that African Americans had concerns about donating that
remained after controlling for attitudes toward research and concerns with privacy.
This latter finding suggests a lack of access to, or unfamiliarity with, research institu-
tions on the part of African Americans (Langford et al. 2014), or distrust in scientific
research among members of this group (Corbie-Smith et al. 2002; Braunstein et al.
2008; McDonald et al. 2014), or both.
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Given the sheer range and varied distribution of NWI’s among the population, we
cannot expect informed consent to do all the ethical work required to promote trust in
biobanking. The informed consent process can be improved, but respect for, and
accommodation of, donors’ NWI’s need not require longer and more complicated con-
sent forms. The imperative of transparency should extend beyond consent to include
policies for disclosure of research being conducted under the auspices of a biobank. Po-
tential donors and the wider public must be given easy access to information about the
types of research being done with donations to biobanks. Such transparency can inform
decisions about donation in ways that will never be captured in a consent form, and
equally important, it can inform donors’ later decisions on whether to withdraw.
Our emphasis on transparency is critical because research ethics regulations are often
inadequate. At present in the United States, Institutional Review Board (IRB) oversight
of biobank research is limited to determining if it does or does not constitute research
on human subjects. And even under the proposed new rules for IRBs in the US, these
committees will have no role after the required blanket consent form is approved. To
respect and accommodate NWIs we must look beyond regulatory schemes and toward
widespread adoption of practices that demonstrate concern for the whole range of
donor NWIs, signaling the trustworthiness of research and dispelling worries that di-
minish the willingness to donate.
Our research has limitations. Although we used a probability-based internet panel to
recruit our respondents, the response rate was just over 60%. While this presents a
challenge to the external validity of our findings, all analyses were weighted to correct
for the stratified sampling designs and other sources of survey errors including non-
coverage and non-response. Internal validity may have been compromised by the suc-
cinct nature of our descriptions of biobanks and the NWI scenarios. For example, we
provided only a brief description of the ethics committee oversight; an actual consent
form might include additional details about this oversight that would lessen partici-
pants’ concerns. We did pilot test these descriptions and concluded that more detailed
descriptions would reduce our response rate and increase the likelihood of varied and
unpredictable interpretations on the part of respondents. Also, our selection of NWI
scenarios, although based on the literature, was such that, given the heterogeneity of
responses to various scenarios, we cannot infer the responses to other potential NWI
scenarios. Finally, our respondents were “hypothetical donors,” and we know that will-
ingness to donate reported on a survey does not always correlate with willingness to
donate in real life situations [Johnsson et al., 2010]. However, it is not clear that “real”
willingness to donate is a more accurate measure of willingness: it may well be that in a
clinical or research setting individuals feel additional social pressure to donate or be
overwhelmed by lengthy and complex consent forms.
Our research confirms that NWI concerns are real and that they influence one’s will-
ingness to donate to a biobank. Ignoring these concerns is problematic, ethically and
pragmatically. It is ethically problematic to gain consent while withholding information
that matters to those giving their consent, and pragmatically, it seems shortsighted to
use a consent process and public information policy that could undermine public trust
in research. Is it possible to find a way to take these interests into account without in-
curring prohibitive costs? And is it possible to both alert people to research they might
find concerning, and at the same time assure them of the positive contributions made
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possible by their participation? We believe such a goal is achievable but in order to im-
prove the consent processes used by, and the transparency of, biobanks it is necessary
to consult the public about their attitudes toward NWIs and their views about whether
and how these should be accommodated by biobanks.
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